Could AIT THERAPEUTICS INC (OTCMKTS:AITB) See a Reversal After More Sellers Came In?

April 17, 2018 - By Dolores Ford

The stock of AIT THERAPEUTICS INC (OTCMKTS:AITB) registered an increase of 600% in short interest. AITB’s total short interest was 1,400 shares in April as published by FINRA. Its up 600% from 200 shares, reported previously. The short interest to AIT THERAPEUTICS INC’s float is 0.05%.

The stock decreased 6.67% or $0.2 during the last trading session, reaching $2.8. About 300 shares traded. AIT Therapeutics, Inc. (OTCMKTS:AITB) has 0.00% since April 17, 2017 and is . It has underperformed by 11.55% the S&P500.

AIT Therapeutics, Inc., a biopharmaceutical company, engages in developing a single proprietary formulation of 160 parts per million of nitric oxide and delivery systems to treat respiratory infections. The company has market cap of $23.51 million. The companyÂ’s pipeline includes therapies against respiratory infections in acute and chronic diseases, such as severe bronchiolitis , cystic fibrosis related lung infections (CF), and non-tuberculosis mycobacterial (NTM) infections. It currently has negative earnings. It has completed two Phase II trials to treat RSV and CF related lung infections, as well as conducted a treatment for patients with CF who suffer from NTM infections.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.